Veeva Systems (NYSE: VEEV) SVP vests RSUs and covers taxes in shares
Veeva Systems SVP and General Counsel, Jonathan Faddis, recently derived 8,726 Class A shares from the vesting of restricted stock units (RSUs). To cover tax obligations, 3,810 shares were withheld by the company at a price of $172.74 per share, which was not a market sale. Following these transactions, Faddis directly holds 8,525 shares of Veeva Systems Class A Common Stock.
Veeva Systems (NYSE: VEEV) CFO nets shares after RSU vesting and tax withholding
Veeva Systems Inc.'s CFO, Brian Van Wagener, exercised 872 Restricted Stock Units (RSUs) on April 1, 2026, converting them into shares of Class A Common Stock. To cover tax obligations, 370 shares were withheld by Veeva at $172.74 per share, which was a tax payment mechanism and not an open-market sale. Following these transactions, the CFO directly holds 8,383 shares of Class A Common Stock.
Veeva Systems (VEEV) exec nets shares after 2,043 RSUs vest
Veeva Systems' President & Chief Customer Officer, Thomas D. Schwenger, settled 2,043 Restricted Stock Units (RSUs) into Class A Common shares on April 1, 2026. To cover tax obligations, 588 shares were withheld by Veeva at $172.74 per share. After these transactions, Schwenger directly holds 23,659 shares of Veeva Systems Class A Common Stock.
Veeva Systems (VEEV) CAO converts RSUs, withholds 957 shares for taxes
Veeva Systems' Chief Accounting Officer, Vipin Kondath, engaged in routine equity compensation activity where 2,603 restricted stock units (RSUs) were converted into Class A Common Stock. To satisfy tax obligations, 957 shares were withheld at a price of $172.74 per share. After these transactions, Kondath directly held 2,676 shares of Class A Common Stock, with the activities noted as exempt from Section 16(b) of the Securities Exchange Act of 1934.
Veeva Systems (NYSE: VEEV) president converts RSUs, retains 31,238 shares
Eleni Nitsa Zuppas, President & Chief of Staff at Veeva Systems (NYSE: VEEV), recently converted 8,998 restricted stock units (RSUs) into Class A Common Stock. A total of 4,002 shares were withheld to cover tax obligations at a price of $172.74 per share, which was not a market transaction. Following these transactions, Ms. Zuppas directly holds 31,238 shares of Class A Common Stock.
Veeva Systems Inc (XTER:VEE) Stock Price, Trades & News
This GuruFocus page provides a comprehensive overview of Veeva Systems Inc (XTER:VEE) stock, including real-time price, key financial metrics, valuation, growth ranks, and news. It also details the company's business description, upcoming earnings dates, and acquisition history, marking it as a leading cloud software provider for the life sciences industry.
Customer Wins, New Products, and AI Investment Support Veeva's Long-Term Growth Momentum
Veeva, a leading cloud-based software provider for the life sciences industry, is supported by customer wins, new product offerings, and investments in AI, ensuring its long-term growth. The company's strategy of focusing on a single industry allows it to tailor solutions precisely to customer needs, enhancing its market penetration and product portfolio. This vertical focus positions Veeva as an attractive offering in its specialized market.
Assessing Veeva Systems (VEEV) Valuation After AOP Health Expands Onto Its Unified Cloud Platforms
Veeva Systems (VEEV) recently saw AOP Health expand its operations onto its cloud platforms, showcasing the deep integration of Veeva's software. Despite this positive news, Veeva's stock has seen a significant decline over the past year, though it shows a slight recovery in the last week. The article discusses Veeva's valuation, noting it's considered undervalued by a key narrative due to potential market expansion and revenue growth, but its P/E ratio suggests the market already factors in optimism.
Here's How Much You Would Have Made Owning Veeva Systems Stock In The Last 10 Years
Veeva Systems (NYSE: VEEV) has significantly outperformed the market over the last decade, with an annualized return of 22.01%. An initial investment of $1000 in VEEV stock ten years ago would now be worth $7,353.17, highlighting the power of compounded returns. The article, generated by Benzinga's automated content engine, emphasizes the substantial growth potential of such investments over time.
VEEV SEC Filings - Veeva Sys Inc 10-K, 10-Q, 8-K Forms
This page provides access to Veeva Systems Inc. (VEEV) SEC filings, including annual reports (10-K), quarterly reports (10-Q), and material event disclosures (8-K). It details recent insider trading activities and the company's strong Q3 financial performance with increased revenue and EPS driven by subscription and professional services. The platform offers AI-powered summaries to help investors understand the significance of each document.
Veeva Systems Buys Ostro As AI Deal Undervalues Share Price
Veeva Systems has acquired Ostro, an AI-powered life sciences brand engagement platform, to enhance its commercial offerings for pharmaceutical and biotech customers. Despite the strategic acquisition leveraging AI for compliant communication with patients and doctors, Veeva's share price is currently undervalued, trading significantly below analyst targets and estimated fair value. Investors will be closely monitoring the integration of Ostro and customer adoption of the new AI tools to assess the deal's impact on Veeva's performance and market valuation.
Veeva Systems (NYSE:VEEV) Emerges as a Strong Growth Stock with a Promising Technical Setup
Veeva Systems (NYSE:VEEV) is highlighted as a compelling investment opportunity, combining strong fundamental growth with a promising technical setup. The company boasts outstanding earnings, a robust financial condition with no debt, and consistent double-digit growth. Technically, VEEV shows signs of basing and potential turnaround after a period of sideways movement, suggesting a favorable entry point for growth-focused investors.
Veeva Systems (NYSE: VEEV) exec pre-planned sale of 1,000 shares
Veeva Systems President & Chief Customer Officer, Thomas D. Schwenger, sold 1,000 shares of Class A common stock at $200.00 per share on March 5, 2026. This pre-planned transaction was executed under a Rule 10b5-1 trading plan adopted on October 14, 2025. Following the sale, Schwenger directly owns 22,204 shares of Veeva Systems.
AOP Health Standardizes on Veeva Industry Cloud for Life Sciences Across All Business Areas
AOP Health, an international biopharma company, has standardized its R&D, quality, commercial, and data operations on Veeva Industry Cloud for Life Sciences. This move aims to accelerate innovation within the company, leveraging the Veeva Vault Platform. The announcement highlights Veeva Systems' continued growth and strong market position.
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), BillionToOne, Inc. Class A (BLLN) and Solventum Corporation (SOLV)
Three analysts recently issued bullish ratings on healthcare companies Veeva Systems (VEEV), BillionToOne, Inc. Class A (BLLN), and Solventum Corporation (SOLV). Wells Fargo assigned a Buy rating to Veeva Systems with a $317 price target, William Blair maintained a Buy rating on BillionToOne, Inc. Class A, and Morgan Stanley upheld a Buy rating for Solventum Corporation with a $103 price target. Based on analyst consensus, all three stocks show significant upside potential from their current levels.
Why Is Veeva Systems Stock Falling Today?
Veeva Systems Inc. (NYSE: VEEV) shares are down today following the announcement of its plan to acquire Ostro, a digital health platform. This acquisition, valued at approximately $100 million, aims to expand Veeva's artificial intelligence tools for pharmaceutical brands to interact with patients and healthcare professionals, reflecting a growing demand for compliant AI communication in healthcare. The deal introduces an AI-powered engagement platform that provides users with verified health information instantly, leveraging conversational AI and semantic search while adhering to compliance safeguards.
AOP Health Standardizes on Veeva Industry Cloud for Life Sciences Across All Business Areas
AOP Health, a biopharma company specializing in rare diseases and critical care, is standardizing its operations on Veeva Industry Cloud for Life Sciences. This move aims to connect its R&D, quality, commercial, and data functions on the Veeva Vault Platform to streamline operations, eliminate silos, and accelerate the delivery of critical medicines. The adoption of Veeva's platform is expected to drive faster global growth and improve patient outcomes by enhancing efficiency and collaboration across various teams.
Veeva Earnings: Strong Close to Fiscal 2026 and Impressive 2027 Guidance Tame Investor Fears
Veeva Systems (VEEV) reported strong fourth-quarter fiscal 2026 results with a 16% year-over-year revenue growth and a 20% increase in adjusted EPS. The company also provided optimistic initial revenue and EPS guidance for fiscal 2027, surpassing FactSet consensus estimates. This positive news led to a 7% jump in shares during early trading.
RSU conversion gives Veeva Systems (NYSE: VEEV) director 253 shares
Veeva Systems director Paul J. Sekhri received 253 shares of Veeva Class A common stock through the vesting and exercise of Restricted Stock Units (RSUs) on March 1, 2026. These RSUs were part of a larger grant from June 2025 under the company's equity incentive plan, and the transaction is exempt from Section 16(b). Following this conversion, Sekhri directly owns 14,938 shares of Class A common stock.
Veeva Earnings Beat Resets Expectations For Vault CRM And AI Transition
Veeva Systems (NYSE:VEEV) announced a strong Q4 earnings beat, generating $835.95 million in revenue and $244.2 million in net income, and issued robust fiscal 2027 revenue guidance of $3.59b-$3.60b. The company also unveiled a new $2 billion share repurchase program and is accelerating customer migration to its Vault CRM platform while expanding AI-driven automation. This combination of strong financial performance, capital return, and strategic product transitions sets new expectations for Veeva's future growth and market positioning.
How Is The Market Feeling About Veeva Systems Inc?
Veeva Systems Inc.'s (NYSE: VEEV) short interest has increased by 26.43% since its last report, indicating a growing bearish sentiment from investors. Currently, 6.33 million shares are sold short, representing 4.21% of its available shares, and it would take traders 2.13 days to cover these positions. Despite the rise, Veeva Systems' short interest is lower than its peer group average of 8.39%.
Why Veeva Systems Shares Are Rocketing After Q4 Results
Veeva Systems (NYSE: VEEV) shares surged after the company reported strong fourth-quarter financial results that exceeded analyst expectations, with revenue up 16% year-over-year to $836 million and EPS of $2.06. The cloud-based software firm also provided optimistic guidance for the first quarter and the next fiscal year, projecting revenue significantly above Street estimates. Leadership attributed this success to strategic initiatives like Veeva AI and strong performance across its commercial, development, and quality cloud segments, aiming for a $6 billion revenue run rate by 2030.
Is Veeva (VEEV) Turning Vault CRM Adoption Into a Deeper Life Sciences Platform Advantage?
Veeva Systems (VEEV) has seen rapid adoption of its Vault CRM platform, with over 125 customers, including top biopharma companies, now live. This shift, coupled with integrated AI capabilities, strengthens Veeva's position as a core commercial platform in life sciences, as it transitions customers from its legacy CRM. While the company forecasts significant revenue and earnings growth, competitive pressure and customer pricing concerns present ongoing risks to its investment narrative.
Veeva Systems (VEEV) director adds shares through RSU conversion and family trust holdings
Veeva Systems (VEEV) director Timothy S. Cabral reported acquiring 262 Class A shares on March 1, 2026, through the vesting of Restricted Stock Units (RSUs) at $0.00 per share. After this transaction, he directly holds 787 Class A shares. Additionally, the Cabral Family Trust, where he is a trustee and beneficiary, indirectly holds 5,500 Class A shares.
Veeva Systems (NYSE: VEEV) director adds shares through 262-unit RSU conversion
Veeva Systems director Priscilla Hung increased her direct ownership by 262 shares of Class A Common Stock through the vesting and conversion of Restricted Stock Units (RSUs) on March 1, 2026. These RSUs were part of a larger grant from June 2025, vesting over time subject to her continued board service. Following this transaction, Hung directly owns 4,753 shares.
Veeva Systems (VEEV) director converts 262 RSUs into Class A shares
Veeva Systems director Mary Lynne Hedley reported an equity award transaction where 262 Restricted Stock Units were converted into Class A common stock on March 1, 2026, at a price of $0.00 per share. Following this conversion, her direct holdings of Class A common stock total 6,890 shares. The RSUs are part of a 1,049-unit grant from June 2025, vesting quarterly subject to her continued service on the board.
Director at Veeva (NYSE: VEEV) acquires stock via RSU vesting
Veeva Systems director Marshall Mohr acquired 288 shares of Class A Common Stock on March 1, 2026, through the exercise of Restricted Stock Units (RSUs) at a price of $0.00 per unit. This transaction is a result of a prior equity award granted on June 18, 2025, which vests quarterly for continued board service. Following the vesting, Mohr now directly holds 5,687 Class A shares and 289 RSUs, with the transaction noted as exempt from Section 16(b).
Veeva Systems (NYSE:VEEV) Sparks Elevated Positioning Chatter In Russell 1000 ETF Today
Veeva Systems (NYSE:VEEV), a company specializing in cloud software for life sciences organizations, is reportedly generating increased attention within the Russell 1000 ETF today. The article highlights Veeva's role in providing specialized platforms for pharmaceutical, biotechnology, and medical device companies. To access the full article, readers are prompted to log in or create an account, suggesting a premium content model.
More Than 125 Customers Worldwide Live on Vault CRM as Veeva Accelerates the Industry's Agentic Transformation
Veeva Systems announced that over 125 customers globally are now live on Veeva Vault CRM, its next-generation CRM for life sciences. This achievement, combined with the availability of Veeva AI, positions Vault CRM as a leader in agentic CRM and accelerates the industry's transformation. The customer base includes top biopharmas and companies across major regions.
More Than 125 Customers Worldwide Live on Vault CRM as Veeva Accelerates the Industry's Agentic Transformation
Veeva Systems announced that over 125 customers globally are now using Veeva Vault CRM, signifying the company's acceleration of agentic CRM in the life sciences industry. The success of Vault CRM, combined with Veeva AI, supports commercial and medical teams across the entire product lifecycle. Veeva has also updated the end-of-support date for Veeva CRM to December 2029 due to the robust adoption of Vault CRM.
Here's Why Artisan Mid Cap Fund Sold Its Position in Veeva Systems (VEEV)
Artisan Mid Cap Fund sold its position in Veeva Systems (VEEV) during Q4 2025, identifying it as a detractor despite solid recurring revenue growth. The decision was driven by rising competitive and AI-driven risks in the life sciences technology sector. The fund believes other AI stocks offer greater upside potential and less downside risk.
Veeva Systems (NYSE:VEEV) Emerges as a Prime GARP Stock Candidate
Veeva Systems (NYSE:VEEV) is highlighted as an ideal "Growth at a Reasonable Price" (GARP) stock, combining strong historic and forecasted growth with a fair valuation relative to its industry and the broader market. The company demonstrates outstanding profitability with high margins and exceptional financial health, characterized by zero debt and high liquidity. These factors position Veeva as a stable investment choice capable of navigating various market conditions.
Veeva QMS BioDlink Win Highlights Valuation Gap In Veeva Systems
Veeva Systems (NYSE:VEEV) recently announced that BioDlink successfully implemented Veeva QMS, a cloud-based quality management platform, highlighting Veeva's role in digital quality for life sciences. Despite this client win, Veeva's stock has seen a significant decline, trading about 43% below analyst targets and 32.1% below Simply Wall St's fair value estimate. This performance suggests a valuation gap, with the stock's recent weakness disconnecting from its fundamental role in the regulated biopharmaceutical sector.
Veeva Systems stock hits 52-week low at $177.82
Veeva Systems (NYSE: VEEV) stock has hit a new 52-week low of $177.82, reflecting a 23.6% decline over the past year and a 32.5% drop in the last six months, with its RSI in oversold territory. Despite the downturn, the company maintains strong financial health, holding more cash than debt, and its stock is trading below its Fair Value according to InvestingPro. Recent developments include a $2 billion share buyback program and mixed analyst ratings, with some downgrading due to maturing products and others upgrading, citing compelling valuation and strong customer migration to Veeva Vault CRM.
Is Veeva (VEEV) Turning Incremental QMS Wins Into a Defensible AI Software Moat?
Veeva Systems (VEEV) recently secured an incremental win with BioDlink implementing its Veeva QMS, reinforcing the stickiness of its specialized software in life sciences. The company is also expanding its AI-enabled tools like Link Key People. Despite concerns about AI disruption eroding the value of specialized vertical tools, this win suggests Veeva could be an AI beneficiary, though its shares might still be trading above fair value.
Veeva Systems Adoption Grows As Valuation Screens Undervalued Versus Targets
Veeva Systems (NYSE:VEEV) is seeing increased adoption of its software in the life sciences sector, with BioDlink implementing Veeva QMS and top biopharmaceutical companies standardizing on Veeva Link Key People. Despite a recent 23% decline in stock price, Simply Wall St assesses Veeva as undervalued, trading about 40% below analyst targets and 29.3% below its fair value estimate. This growing integration into critical pharma workflows suggests potential for sustained growth, though investors should monitor customer adoption trends and share price momentum.
13 of the Top 20 Biopharmas Standardize Globally on Veeva Link Key People
Veeva Systems announced that 13 of the top 20 biopharmaceutical companies have standardized on Veeva Link Key People for enhanced customer engagement and AI-driven data. This platform provides critical insights to medical and commercial teams, supports AI initiatives, and has seen significant adoption, including 38 new customers and three top biopharmas making it their global standard within the last year. Recent innovations like AI-powered summaries and the Link Direct Data API further improve utility for the life sciences industry.
Veeva: We Think Shares are Cheap After Recent Selloff on Growth and Customer Retention Concerns
Veeva shares have significantly declined, trading near a 52-week low after hitting a three-year high in October 2025. The selloff, which saw shares drop roughly 25% since the third-quarter earnings report in late November, has led Morningstar to believe the stock is now undervalued. This assessment comes despite concerns over customer retention and growth, with analysts suggesting the dip presents a buying opportunity.
Does Veeva’s AI‑Ready Quality Platforms Reshape the Bull Case For Veeva Systems (VEEV)?
Veeva Systems (VEEV) is leveraging its AI-ready QualityOne and unified data platforms to help life sciences and consumer goods companies operationalize AI, overcoming legacy system and compliance hurdles. This AI-readiness narrative is sharpening Veeva's investment thesis, potentially providing near-term catalysts, although it also increases execution risk given the company's premium valuation. Investors are advised to consider the potential downside as the stock may still be trading above its fair value despite recent pullbacks.
Veeva Announces eSource Application for Research Sites to Eliminate Paper and Streamline Clinical Trial Data Flow
Veeva Systems has announced Veeva eSource, a new application within Veeva SiteVault, aimed at revolutionizing clinical trial data management. This innovation seeks to eliminate paper, reduce manual processes, and enhance data quality by integrating Electronic Health Records (EHR) and Electronic Data Capture (EDC) systems. The initiative is designed to simplify and standardize clinical trials, improving efficiency and experience for sponsors, sites, and patients, with early adopter availability planned for the second half of 2026.
Veeva Systems Inc. (NYSE:VEEV) Emerges as a Top GARP Stock Pick
Veeva Systems Inc. (NYSE:VEEV) has been identified as a top Growth at a Reasonable Price (GARP) stock, demonstrating solid growth prospects, a fair valuation, and strong foundational strength. The company exhibits robust past and projected growth in EPS and revenue, coupled with a reasonable Price/Earnings ratio compared to its health care technology peers. Furthermore, Veeva boasts exceptional earnings margins, high returns on capital, and a debt-free balance sheet, underscoring its financial soundness.
Veeva Systems (NYSE:VEEV) Emerges as a Strong Growth Pick with Bullish Technical Setup
Veeva Systems (NYSE:VEEV) is identified as a strong growth pick due to its robust fundamental characteristics and an emerging bullish technical setup. The company demonstrates excellent profitability, financial health with no debt, and consistent growth in EPS and revenue. Technically, the stock shows signs of resting after a decline, with clear support levels, suggesting a potential turn upwards once accumulation ends.
Veeva Systems (VEEV) Is Up 8.0% After First Buyback And New GMP Cloud Launch - Has The Bull Case Changed?
Veeva Systems announced its first share repurchase program of up to $2 billion and launched a new cloud-native Environmental Monitoring solution, strengthening its financial toolkit and role in life sciences manufacturing. While these developments support Veeva's platform story, they don't alter the near-term focus on AI-driven Vault adoption or competitive risks. The company projects $4.3 billion revenue and $1.3 billion earnings by 2028, with a fair value estimate of $312.18, suggesting a 29% upside from its current price.
Is It Time To Reconsider Veeva Systems (VEEV) After AI Agents Rollout?
This article analyzes Veeva Systems (VEEV) stock valuation using Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) ratio methods. The DCF model suggests Veeva Systems is undervalued by 17.5%, while its current P/E of 43.66x indicates it is overvalued compared to its "Fair Ratio" of 32.34x. The piece encourages investors to utilize "Narratives" for personalized valuation based on individual assumptions and highlights mixed recent stock returns.
Veeva approves $2B plan to buy back its own stock over 2 years
Veeva Systems (VEEV) announced that its board approved a share repurchase program, authorizing the purchase of up to $2 billion of its Class A common stock over a two-year period. The program allows for open-market, privately negotiated transactions, or Rule 10b5-1 trading plans, but does not obligate Veeva to acquire a specific number of shares and can be suspended or canceled at any time. This move adds a capital return dimension to Veeva's growth story following strong financial performance and product expansion.
Veeva Announces Environmental Monitoring Solution to Modernize Quality Control in Manufacturing
Veeva Systems has announced a new environmental monitoring (EM) solution, integrated with Veeva LIMS, to enhance quality control in manufacturing. This cloud-native application will automate the scheduling, collection, and analysis of environmental samples to ensure compliance with GMP standards. The solution, part of Veeva Quality Cloud, aims to eliminate data silos and paper-based processes by integrating with other Veeva applications like Veeva QMS, Veeva QualityDocs, and Veeva Batch Release, streamlining the batch release process for life sciences companies.
Novo Nordisk International Operations Commits to Veeva Vault CRM
Novo Nordisk's International Operations business unit has committed to adopting Veeva Vault CRM to enhance its commercial execution and leverage next-generation CRM capabilities and agentic AI. This expansion of their partnership with Veeva Systems aims to support Novo Nordisk in delivering breakthrough medicines globally. Veeva Vault CRM, part of the broader Vault CRM Suite, offers advanced global capabilities designed to meet the life sciences industry's specific business and compliance requirements.
Veeva Systems Announces First-Ever $2 Billion Share Buyback
Veeva Systems (VEEV) has announced its first-ever share repurchase program, authorizing the buyback of up to $2 billion of its Class A common stock over two years. This move aims to return capital to shareholders and demonstrates confidence in the company's long-term growth. While a recent analyst rating is a "Buy" with a $320 target, TipRanks' AI Analyst, Spark, rates VEEV as "Neutral" due to a balance of strong financial performance and strategic initiatives against bearish technical indicators and a high P/E ratio.
Veeva Announces Share Repurchase Program
Veeva Systems Inc. announced that its Board of Directors approved a share repurchase program authorizing the company to purchase up to $2 billion of its Class A common stock. This program reflects the company's confidence in its long-term growth and commitment to returning capital to shareholders, supported by its strong financial performance and cash generation. The repurchases will be made over a two-year term, with timing and amount determined at management's discretion.
Veeva Systems To Buy Back Up To $2 Bln Of Shares Of Its Class A Common Stock
Veeva Systems Inc. announced that its Board of Directors has approved a share repurchase program authorizing the purchase of up to $2 billion of its Class A common stock. This program has a 2-year term and does not obligate Veeva to acquire a specific number of shares, as it can be canceled or suspended at any time.
